Stereotactic radiotherapy for bone oligometastases

Caterina Colosimo¹, Francesco Pasqualetti², Cynthia Aristei³, Simona Borghesi¹, Letizia Forte³, Marcello Mignogna¹, Donatella Badii², Manrico Bosio², Fabiola Paia², Sara Nanni¹, Silvia Bertocci⁴, Luciana Lastrucci³, Silvana Parisi³, Gianluca Ingrosso³

¹Operative Unit of Radiotherapy, Department of Oncology, San Luca Hospital, Lucca, Italy
²Department of Radiation Oncology, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Italy
³Radiation Oncology Section, University of Perugia and Perugia General Hospital, Italy
⁴Radiation Oncology Unit of Arezzo-Valdarno, Azienda USL Toscana Sud Est, Italy
⁵Department of Radiotherapy, Livorno Hospital, ATNO, Italy
⁶Radiation Oncology Unit — Department of Biomedical, Dental Science, and Morphological and Functional Images, University of Messina, Italy

ABSTRACT

About 60–90% of cancer patients are estimated to develop bone metastases, particularly in the spine. Bone scintigraphy, computed tomography (CT) and magnetic resonance imaging (MRI) are currently used to assess metastatic bone disease; positron emission tomography/computed tomography (PET-CT) has become more widespread in clinical practice because of its high sensitivity and specificity with about 95% diagnostic accuracy. The most common and well-known radiotracer is 18F-fluorodeoxyglucose (¹⁸FDG); several other PET-radiotracers are currently under investigation for different solid tumors, such as ¹¹C or ¹⁸FDG-choline and prostate specific membrane antigen (PSMA)-PET/CT for prostate cancer. In treatment planning, standard and investigational imaging modalities should be registered with the planning CT so as to best define the bone target volume. For target volume delineation of spine metastases, the International Spine Radiosurgery Consortium (iSRC) of North American experts provided consensus guidelines. Single fraction stereotactic radiotherapy (SRT) doses ranged from 12 to 24 Gy; fractionated SRT administered 21–27 Gy in 3 fractions or 20–35 Gy in 5 fractions. After spine SRT, less than 5% of patients experienced grade ≥ 3 acute toxicity. Late toxicity included the extremely rare radiation-induced myelopathy and a 14% risk of de novo vertebral compression fractures.

Key words: stereotactic radiotherapy; radiosurgery; oligometastasis; bone metastases; spine metastases; hypofractionation; local control; toxicity

Rep Pract Oncol Radiother 2022;27(1):40–45

Introduction

Solid tumors frequently spread to bones, most often the spine. About 60–90% of cancer patients are estimated to develop bone metastases [1, 2] which are associated with increased risk of complications such as pain, fractures and hypercalceemia. At the metastatic site, bone remodeling due to increased osteoblast and osteoclast activity seems to alter the microenvironment, promoting tumor growth and bone destruction. From the diagnostic point of view, this tissue remodeling is characterized by lytic and thickened areas within the bone [3].

In terms of survival, there is a huge heterogeneity between different histotypes with diverse molecu-
lar phenotypes. For instance, prognosis is better in breast cancer patients with only bone involvement than in those with visceral metastases [4]. Moreover, patients with oligometastatic bone disease and few secondary localizations might be candidates for curative therapy [5, 6].

This overview provides a critical appraisal of the current evidence and future perspectives of bone oligometastatic disease.

**Sources of information**

By February 2021, Pubmed and the Cochrane library were searched for relevant literature.

**Diagnostic imaging and target volume definition**

Bone scintigraphy, computed tomography (CT) and magnetic resonance imaging (MRI) are currently used to assess metastatic bone disease [7–9]. Bone scintigraphy has the advantage of detecting lesions with a low bone-matrix turnover, although false negatives may occur in lytic lesions without tissue remodeling [10, 11]. Over the past few years, the use of the positron emission tomography/computed tomography (PET/CT) has become more widespread in clinical practice because of its high sensitivity and specificity in detecting bone metastasis, even lytic lesions, and its diagnostic accuracy of about 95% [12–15]. The most common and well-studied radiotracer is 18F-fluorodeoxyglucose (18FDG). With it, the PET/CT achieves the same sensitivity as, and greater specificity than, bone scintigraphy (96% vs. 66%) [14, 15]. Several other PET-radiotracers are currently under investigation for different solid tumors. For instance, 11C or 18FDG-choline and prostate specific membrane antigen (PSMA)-PET/CT are used for staging recurrent prostate cancer which might benefit from metastasis-directed therapy when an oligometastatic state is detected [16–18].

In radiation oncology, standard and investigation-al imaging modalities should be registered with the planning CT in order to define the bone target volume better. More specifically, MRI is the most sensitive in defining bone lesions and critical structures, such as the spinal cord, that need to be spared from irradiation. The International Spine Radiosurgery Consortium (ISRC) of North American experts in radiosurgery provided consensus guidelines for target volume delineation in spine SRT [19]. The gross tumour volume (GTV) has to be fully contoured whereas the clinical target volume (CTV) is defined according to the involved vertebral region: the vertebral body, pedicle, transverse process, lamina or spinous process. For example, when the lesion involves the spinous process the CTV encompasses the entire spinous process and bilateral laminae. When it is detected in any part of the vertebral body, the entire vertebral body must be included in the CTV. For extended metastases involving the vertebral body and bilateral pedicles, the CTV should encompass the entire vertebral body, bilateral pedicles, transverse processes and bilateral laminae. A circumferential CTV around the cord is not recommended when lesions involve the entire vertebral body, bilateral pedicles and spinous process as it should be used only in rare cases of massive vertebral involvement [19]. In spine stereotactic radiotherapy (SRT) the planning target volume (PTV) and planning organ at risk volume (PRV) margins should be determined on an institution-to-institution basis because these geometrical expansions depend on the immobilization system, treatment planning, image-guided technique and fractionation scheme.

**Fractionation schedules and dose constraints to the organs at risk (OARs)**

Although the safety and efficacy of spine SRT were reported in many retrospective series, consensus is still lacking on the optimal dose fractionation. Most treatments were delivered as single fractions, with doses ranging from 12 to 24 Gy [20, 21], or fractionated schedules with total doses of 21–27 Gy being administered in 3 fractions or 20–35 Gy in 5 fractions [22–24]. In a retrospective series of spinal metastases from different solid tumors, Heron et al. reported that no differences emerged in long-term pain control and toxicity after a 16.3 Gy spinal single dose or hypofractionated schedules (20–24 Gy in 3–5 fractions). SRT in single dose had a worse rate of 2-year local control (70% vs. 96%) and was associated with a higher re-treatment rate [25]. In patients with 1–3 spine metastases the phase II/III RTOG 0631 trial [26] demonstrated the safety of a single 16 Gy dose. In patients with spine metastases Wang et al. [23] prospectively analyzed outcomes after hy-
pofractionated schemes (27–30 Gy in 3 fractions). No G4 toxicity was reported and local control, as assessed by MRI, was achieved in 72% of cases. Ahmed et al. [27], administered a total median dose of 24 Gy (range, 10–40 Gy) in 3 fractions (range, 1–5), achieving a 1-year local control of 91.2%. In oligometastatic patients, a phase III prospective randomized trial evidenced that a single high-dose of 24 Gy compared with hypofractionated SRT (3 × 9 Gy) was more effective in ablating bone metastases and led to a better time to distant metastatic progression [28]. Several studies showed that the primary tumor histology might influence the efficacy of ablative radiotherapy, as SRT seemed more effective in breast metastases than in melanoma or renal cell carcinoma metastases (100% vs. 75%) [29]. For instance, in a recent retrospective analysis of 605 patients treated with hypofractionated SRT (total dose 20–28 Gy in two daily fractions) for 1,406 spine metastases multivariate analysis showed that less radiosensitive histologies were associated with a worse outcome [29]. In radioresistant tumors, a single dose > 20 Gy might be considered to achieve high local control rates (95–100%) [28, 30–33].

Spine SRT was investigated in selected cases of cord compression [34, 35]. More specifically, total doses of 14–27 Gy in 1–3 fractions were delivered to the target volume encompassing the epidural mass and the vertebral body that was involved. A local control rate of 80% was reported [34, 35]. After surgical decompression, spine SRT might increase the local control rate. To date, few retrospective analyses and some phase I/II studies have reported local control rates ranging from 70% to 100% after single doses of 14–24 Gy or fractionated doses of 27–30 Gy in 3–5 fractions [36–40].

When treating spine metastases, sparing the spinal cord from high doses is crucial. The American Association of Physicists in Medicine (AAPM) Task Group 101 provided information about dose constraints to the OARs for SRT. If single fraction SRT is delivered < 1 cm³ of cord tissue should receive < 7 Gy. Otherwise, the total dose to 1 cm³ of cord tissue must be < 12.3 Gy and < 14.5 Gy when SRT is administered in 3 or 5 fractions, respectively. The maximum dose to the cord must be < 10 Gy for a single fraction, < 18 Gy for 3 fractions, and < 23 Gy for 5 fractions. In the RTOG 0631 trial, no more than 10% of spinal cord (defined as the cord corresponding to the metastatic vertebra plus 5 mm above and below the PTV) had to receive a total dose > 10 Gy [26]. The UK consensus on OAR dose constraints for SRT suggests a total maximum dose to the cord of 10 Gy, 18 Gy, 23 Gy and 25 Gy in 1, 3, 5 and 8 fractions, respectively [41].

### Toxicity

Spine SRT was most commonly associated with the following acute toxicity: grade 1 or 2 fatigue and skin erythema. In 23–68% of patient transient pain flare occurred [42, 43], the incidence of which was significantly reduced by dexamethasone during SRT [44]. Acute gastro-intestinal symptoms, due to mucositis, were linked to the irradiation site (i.e., cervical, thoracic or lumbar spine). Under 5%

---

**Table 1. Spine stereotactic radiotherapy (SRT) schedules and local control**

| Author (year)         | No. of pts | Median total dose (range)/Median no. of fractions (range) | Median follow-up [months] (range) | Local control (%) |
|-----------------------|------------|------------------------------------------------------------|-----------------------------------|-------------------|
| Anand et al. (2015)   | 52         | 24 Gy (24–27 Gy)/3 (1–3)                                   | 8.5 (3–40)                        | 82.6              |
| Guckenberger et al. (2014) | 301       | 24 Gy (10–60 Gy)/3 (1–20)                                  | 11.8 (0–105)                      | 83.9              |
| Ahmed et al. (2012)   | 46         | 24 Gy (10–40 Gy)/3 (1–5)                                   | Mean 8.2                          | 91.2              |
| Wang et al. (2012)    | 149        | 27–30 Gy/3                                                 | 15.9 (1–91.6)                     | 72.4              |
| Yamada et al. (2008)  | 93         | 24 Gy (18–24 Gy)/1                                         | 15 (2–45)                         | 90                |
| Gerszten et al. (2007)| 156 (no. of lesions) | 20 Gy (12.5–25 Gy)/1                                      | 21 (3–53)                         | 90                |
of patients experienced grade ≥ 3 acute toxicity [22, 23, 27, 38, 40].

Late toxicity included the extremely rare radiation-induced myelopathy and a 14% risk of de novo vertebral compression fractures (VCF) [45]. These severe complications can occur from 6 months to 3 years after radiotherapy. Spinal instability is assessed by the Spinal Instability Neoplastic Score (SINS) [46, 47] with scores ≥ 7 predicting increased risk of VCF after spine SRT [48].

**Conclusions**

A few data from the literature reported significant differences in the doses and fractionations used for SRT in bone oligometastatic disease, which were generally chosen on the basis of primary tumour histology and bio-pathological characterization, target volume size, location and its relationship with OARs. In most studies SRT was delivered to spinal bone metastases and only a few studies included other sites of disease. Furthermore, heterogeneity in study populations was observed. Although better results were achieved in oligometastases from radiosensitive than radioresistant primary disease, no firm indications emerged on patient selection [49, 50]. At present, the only limitation in delivering SRT is treatment safety, which can vary case-by-case. All these uncertainties suggest the need for clinical trials and consensus guidelines.

**Conflicts of interest**

The authors have no conflict of interest to declare.

**Funding**

This publication was prepared without any external source of funding.

**Ethical permission**

Ethical approval was not necessary for the preparation of this article.

**References**

1. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9(4): 239–252, doi: 10.1038/nrc2618, indexed in Pubmed: 19279573.
2. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12(20 Pt 2): 6243s–6249s, doi: 10.1158/1078-0432.CCR-06-0931, indexed in Pubmed: 17062708.
3. Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med. 1998; 25(9): 1244–1247, doi: 10.1007/s002590050291, indexed in Pubmed: 9724372.
4. Jacobson AF, Shapiro CL, Van den Abbeele AD, et al. Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer. 2001; 91(1): 17–24, doi: 10.1002/1097-0142(20010101)91:1<17::aid-cncr3>3.0.co;2-k, indexed in Pubmed: 11148555.
5. Nikura N, Liu J, Hayashi N, et al. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist. 2011; 16(2): 155–164, doi: 10.1634/theoncologist.2010-0350, indexed in Pubmed: 21266401.
6. D’Angelillo RM, Francolini G, Ingrasso G, et al. Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). Crit Rev Oncol Hematol. 2019; 138: 24–28, doi: 10.1016/j.critrevonc.2019.03.014, Indexed in Pubmed: 31092381.
7. Lecouvet FE, Geuken D, Stainer A, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol. 2007; 25(22): 3281–3287, doi: 10.1200/JCO.2006.09.2940, indexed in Pubmed: 17664475.
8. Yilmaz MH, Ozguroglu M, Mert D, et al. Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study. Med Oncol. 2008; 25(3): 257–263, doi: 10.1007/s12032-007-9027-x, indexed in Pubmed: 18040900.
9. Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med. 2001; 45: 53–64.
10. Taoka T, Mayr NA, Lee HJ, et al. Factors influencing visualization of vertebral metastases on MR imaging versus bone scintigraphy. AJR Am J Roentgenol. 2001; 176(6): 1525–1530, doi: 10.2214/ajr.176.6.1761525, indexed in Pubmed: 11373226.
11. Messiou C, Cook G, deSouza NM. Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer. 2009; 101(8): 1225–1232, doi: 10.1038/sj.bjc.6605334, indexed in Pubmed: 19789531.
12. Greco C, Clifton Ling C. Broadening the scope of image-guided radiotherapy (iGRT). Acta Oncol. 2008; 47(7): 1193–1200, doi: 10.1080/02841860802241956, indexed in Pubmed: 18618298.
13. Taia ALV, Herfkens RJ, Gambhir SS, et al. Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology. 2007; 243(1): 204–211, doi: 10.1148/radiol.2431052104, indexed in Pubmed: 17392254.
14. Ožšüker T, Küçüköz UzuN A, Ožšüker F, et al. Comparison of (18)F-FDG-PET/CT with (99m)Tc-MDP bone scintigraphy for the detection of bone metastases in cancer patients. Nucl Med Commun. 2010; 31(6): 597–603, doi: 10.1097/MNM.0b013e328338e909, indexed in Pubmed: 20224457.
15. Song JW, Oh YM, Shim TS, et al. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer.

https://journals.viamedica.pl/rpor

Caterina Colosimo et al. SRT for bone oligometastases
Lung Cancer. 2009; 65(3): 333–338, doi: 10.1016/j.jlungen.2008.12.004, indexed in Pubmed: 19144446.

16. Nitsch S, Hakenberg OW, Heuschkel M, et al. Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging. J Nucl Med. 2016; 57(Suppl 3): 385–425, doi: 10.2967/jnumed.115.169748, indexed in Pubmed: 27694169.

17. Pasqualetti F, Cocuzza P, Coraggio G, et al. Long-term PSA in a Patient with Oligometastatic Castration-Resistant Prostate Cancer. Oncol Res Treat. 2016; 39(4): 217–220, doi: 10.1159/0004444906, indexed in Pubmed: 27160394.

18. Fodor A, Lancia A, Ceci F, et al. Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row: Nodal oligorecurrent prostate cancer. World J Urol. 2019; 37(12): 2607–2613, doi: 10.1007/s00345-018-2322-7, indexed in Pubmed: 29752513.

19. Cox BW, Spratt DE, Lovelock M, et al. International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012; 83(5): e597–e605, doi: 10.1016/j.ijrobp.2012.03.009, indexed in Pubmed: 22608954.

20. Gerszten PC, Burton SA, Ozhasoglu C, et al. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976). 2007; 32(2): 193–199, doi: 10.1097/01.brs.0000251863.76595.a2, indexed in Pubmed: 17724814.

21. Nguyen QN, Shiu AS, Rhines LD, et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 76(4): 1185–1192, doi: 10.1016/j.ijrobp.2009.03.062, indexed in Pubmed: 19632064.

22. Guckenberger M, Mantel F, Gerszten PC, et al. Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiat Oncol. 2014; 9: 226, doi: 10.1186/s13014-014-0226-2, indexed in Pubmed: 25319530.

23. Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol. 2012; 13(4): 395–402, doi: 10.1016/S1470-2045(11)70384-9, indexed in Pubmed: 22285199.

24. Park HJ, Griffin RJ, Hui S, et al. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012; 177(3): 311–327, doi: 10.1667/rrr2773.1, indexed in Pubmed: 2229487.

25. Heron DE, Rajagopalan MS, Stone B, et al. Single-session and multisession CyberKnife radiosurgery for spine metastases–University of Pittsburgh and Georgetown University experience. J Neurosurg Spine. 2012; 17(1): 11–18, doi: 10.3171/2012.4.SPINE11902, indexed in Pubmed: 22578235.

26. Ryu S, Pugh SL, Gerszten PC, et al. TOTG 0631 Phase II/III Study of Image-Guided Stereotactic Radiosurgery for Locally Advanced (1-3) Spine Metastases: Phase II Results. Int J Radiat Oncol Biol Phys. 2011; 81(2): S131–S132, doi: 10.1016/j.ijrobp.2011.03.001, indexed in Pubmed: 23864755.

27. Ahmed KA, Stauber MC, Miller RC, et al. Stereotactic body radiation therapy in spinal metastases. Int J Radiat Oncol Biol Phys. 2012; 82(5): e803–e809, doi: 10.1016/j.ijrobp.2011.11.036, indexed in Pubmed: 22330988.

28. Zelefsky MJ, Yamada Y, Greco C, et al. Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer. Int J Radiat Oncol Biol Phys. 2021; 110(3): 672–679, doi: 10.1016/j.ijrobp.2021.01.004, indexed in Pubmed: 33422612.

29. Zeng KL, Saghal A, Tseng CL, et al. Prognostic Factors Associated with Surviving Less Than 3 Months vs Greater Than 3 Years Specific to Spine Stereotactic Body Radiotherapy and Late Adverse Events. Neurosurgery. 2021; 88(5): 971–979, doi: 10.1093/neuros/nyaa583, indexed in Pubmed: 33475723.

30. Zelefsky MJ, Greco C, Motzer R, et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys. 2011; 79(4): 1151–1157, doi: 10.1016/j.ijrobp.2009.12.038, indexed in Pubmed: 20510337.

31. Zelefsky MJ, Greco C, Motzer R, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012; 82(5): 1744–1748, doi: 10.1016/j.ijrobp.2011.02.040, indexed in Pubmed: 21596489.

32. Yamada Y, Bilsky MH, LoveLock DM, et al. High-dose single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008; 71(2): 484–490, doi: 10.1016/j.ijrobp.2007.11.046, indexed in Pubmed: 18234445.

33. Siva S, Louie AV, Warner A, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer. 2018; 124(5): 934–942, doi: 10.1002/cncr.31156, indexed in Pubmed: 29266183.

34. Ryu S, Rock J, Jain R, et al. Radiosurgical decompression of metastatic epidural compression. Cancer. 2010; 116(9): 2250–2257, doi: 10.1002/cncr.24993, indexed in Pubmed: 20209611.

35. Anand AK, Venkadam-Mickam G, Punnakal AU, et al. Hypofractionated stereotactic body radiotherapy in spinal metastasis — with or without epidural extension. Clin Oncol (R Coll Radiol). 2015; 27(6): 345–352, doi: 10.1016/j.clon.2015.01.035, indexed in Pubmed: 25726363.

36. Garg AK, Shiu AS, Yang J, et al. Phase 1/2 trial of single-session stereotactic body radiation therapy for previously unirradiated spinal metastases. Cancer. 2012; 118(20): 5069–5077, doi: 10.1002/cncr.27530, indexed in Pubmed: 22511344.

37. Tao R, Bishop AJ, Brownlee Z, et al. Stereotactic Body Radiation Therapy for Spinal Metastases in the Postoperative Setting: A Secondary Analysis of Mature Phase 1-2 Trials. Int J Radiat Oncol Biol Phys. 2016; 95(5): 1405–1413, doi: 10.1016/j.ijrobp.2016.03.022, indexed in Pubmed: 27209509.

38. Al-Omair a, Massucci L, Masson-cote l, et al. Surgical resection of epidural disease improves local control following postoperative spine stereotactic body radiotherapy. Neuro Oncol. 2013; 15(10): 1413–1419, doi: 10.1093/neuroon/not101, indexed in Pubmed: 24057886.

39. Gerszten PC, Germanwala A, Burton SA, et al. Combination kyphoplasty and spinal radiosurgery: a new treatment approach for spinal metastases from renal cell carcinoma: A University experience. J Neurosurg Spine. 2012; 17(1): 30–38, doi: 10.1093/jnurocl/not101, indexed in Pubmed: 24057886.
40. Laufer I, Iorgulescu JB, Chapman T, et al. Local disease control for spinal metastases following “separation surgery” and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine. 2013; 18(3): 207–214, doi: 10.3171/2012.11.SPINE12111, indexed in Pubmed: 2339593.

41. Hanna GG, McDonald F, Murray L, et al. UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clin Oncol (R Coll Radiol). 2018; 30(1): 5–14, doi: 10.1016/j.clon.2017.09.007, indexed in Pubmed: 29033164.

42. Pan HY, Allen PK, Wang XS, et al. Incidence and predictive factors of pain flare after spine stereotactic body radiation therapy: secondary analysis of phase 1/2 trials. Int J Radiat Oncol Biol Phys. 2014; 90(4): 870–876, doi: 10.1016/j.ijrobp.2014.07.037, indexed in Pubmed: 25227497.

43. Chiang A, Zeng L, Zhang L, et al. Pain flare is a common adverse event in steroid-naïve patients after spine stereotactic body radiation therapy: a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2013; 86(4): 638–642, doi: 10.1016/j.ijrobp.2013.03.022, indexed in Pubmed: 23664326.

44. Khan L, Chiang A, Zhang L, et al. Prophylactic dexamethasone effectively reduces the incidence of pain flare following spine stereotactic body radiotherapy (SBRT): a prospective observational study. Support Care Cancer. 2015; 23(10): 2937–2943, doi: 10.1007/s00520-015-2659-z, indexed in Pubmed: 25752882.

45. Sahgal A, Atenafu EG, Chao S, et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol. 2013; 31(27): 3426–3431, doi: 10.1200/JCO.2013.50.1411, indexed in Pubmed: 23960179.

46. Fisher CG, Di Pa, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine, Philadelphia 2010: E1221–E1229.

47. Fisher CG, Schouten R, Versteeg AL, et al. Reliability of the Spinal Instability Neoplastic Score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases. Radiat Oncol. 2014; 9: 69, doi: 10.1186/1748-717X-9-69, indexed in Pubmed: 24594004.

48. Lee SH, Tatsui CE, Ghia AJ, et al. Can the spinal instability neoplastic score prior to spinal radiosurgery predict compression fractures following stereotactic spinal radiosurgery for metastatic spinal tumor?: a post hoc analysis of prospective phase II single-institution trials. J Neurooncol. 2016; 126(3): 509–517, doi: 10.1007/s11060-015-1990-z, indexed in Pubmed: 26643804.

49. Nguyen TK, Sahgal A, Dagan R, et al. Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: International Practice Patterns to Guide Treatment Planning. Pract Radiat Oncol. 2020; 10(6): e452–e460, doi: 10.1016/j.prro.2020.02.011, indexed in Pubmed: 32171852.

50. Spencer KL, van der Velden JM, Wong E, et al. Systematic Review of the Role of Stereotactic Radiotherapy for Bone Metastases. J Natl Cancer Inst. 2019; 111(10): 1023–1032, doi: 10.1093/jnci/djz101, indexed in Pubmed: 31119273.